{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-019437","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.092060+00:00","generated_at":"2026-05-25T16:56:24.758107+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Oramed enters royalty purchase on Gloperba/Elyxyb and rest-of-world license for Gloperba","bullets":["Oramed gains right to 50% of 4% net sales royalty on Gloperba and Elyxyb worldwide (effectively 2% of net sales).","Oramed via RoyaltyVest Ltd gets exclusive rest-of-world license for Gloperba; net revenue split 50/50 with Scilex.","Agreements executed Feb 28, 2025 as part of deferral on $50M Scilex convertible notes due Oct 2026.","Oramed transferred 50% of RoyaltyVest shares to other investors; retains right to designate half the board.","Subordination Agreement grants first-priority lien on royalty collateral to Oramed and other purchasers."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-019437","json":"https://secwatch.observer/filing/0001213900-25-019437.json","markdown":"https://secwatch.observer/filing/0001213900-25-019437.md","text":"https://secwatch.observer/filing/0001213900-25-019437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025019437/0001213900-25-019437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025019437/ea0232721-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T16:56:24.758107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}